A Novel Anti-CEACAM5 Monoclonal Antibody, CC4, Suppresses Colorectal Tumor Growth and Enhances NK Cells-Mediated Tumor Immunity
2011

A Novel Anti-CEACAM5 Monoclonal Antibody, CC4, Suppresses Colorectal Tumor Growth and Enhances NK Cells-Mediated Tumor Immunity

Sample size: 14 publication 10 minutes Evidence: high

Author Information

Author(s): Zheng Chaogu, Feng Jing, Lu Di, Wang Ping, Xing Shu, Coll Jean-Luc, Yang Dongling, Yan Xiyun

Primary Institution: National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, People's Republic of China

Hypothesis

Can the anti-CEACAM5 monoclonal antibody CC4 inhibit colorectal tumor growth and enhance NK cell-mediated immunity?

Conclusion

The anti-CEACAM5 monoclonal antibody CC4 significantly suppresses colorectal tumor growth and enhances NK cell activity against cancer cells.

Supporting Evidence

  • CC4 specifically binds to colorectal cancer cells and inhibits their growth.
  • CC4 enhances NK cell-mediated cytotoxicity against CEACAM5-expressing cancer cells.
  • Treatment with CC4 resulted in significantly smaller tumors in mice compared to controls.
  • CC4 disrupts the inhibitory interaction between CEACAM1 on NK cells and CEACAM5 on tumor cells.

Takeaway

Researchers created a special antibody that can find and fight colorectal cancer cells, helping the body's immune system do its job better.

Methodology

The study involved generating the CC4 antibody, testing its binding to cancer cells, and evaluating its effects on tumor growth in mice and NK cell activity.

Limitations

The study primarily focused on in vivo models and may not fully represent human responses.

Participant Demographics

Mice were used for the experiments, specifically BALB/c and nude mice.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.01

Digital Object Identifier (DOI)

10.1371/journal.pone.0021146

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication